Since cholecystokinin 2 receptor (CCK2R) is overexpressed in lung, colon, thyroid, pancreatic, and GC, but is largely absent in most non-tumor tissues [92], Wayua and colleagues developed an NIR ligand that targets CCK2R-positive tumors. Here, CCKBR is linked to neoplasm.